5’ Cap Analog
[INQ. NO. 2309C11] Hanmi Cap, a revolutionary 5’ cap analog, is a critical raw material, pivotal in mRNA vaccine and therapeutic developments. The necessity of a 5’ cap analog in an mRNA vaccine lies in its ability to bind with the eIF4E (translation initiation factor) for the successful expression of proteins, thereby making the vaccine functional.

The Pfizer/BioNTech COVID-19 vaccine utilizes a 5’ cap analog known as CleanCap, developed by Trilink in the United States, and currently monopolizes the market.

Hanmi Cap, however, circumvents the CleanCap patent, boasting equivalent or superior efficacy while offering a competitive edge in pricing. Feedback from mRNA vaccine developers suggests the prohibitive costs of CleanCap have hampered vaccine development, positioning the Hanmi Cap as an attractive, cost-effective alternative.

Thanks to a maximized efficient GMP production process, Hanmi Cap can be supplied at a lower unit cost compared to competing products. The product has demonstrated outstanding performance in protein expression efficacy tests across different mRNA platforms.

Thus, Hanmi Cap has the potential to be an ideal alternative for pharmaceutical companies and researchers developing mRNA vaccines or therapeutics.

The company behind this game-changing product, Hanmi Fine Chemical Co., Ltd., has over 30 years of experience in producing and exporting Active Pharmaceutical Ingredients (APIs). They have maintained a prominent position in the cGMP field through robust research capabilities, production facilities, and quality-control systems.

After successfully establishing itself in the production of cephalosporin antibiotics and overcoming patent hurdles in non-cephalosporin products, the company is now focusing on the production of the indispensable 5’ cap analog for mRNA vaccine and therapeutic development.

Korean-Products.com | Blog Magazine of Korean products, brands and Goods